Garrison Bradford & Associates’s VistaGen Therapeutics VTGN Stock Holding History

Garrison Bradford & Associates’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-667	Closed	-$25K	–	56
2022 Q1	$25K	Hold	667	–	–	0.02%	57
2021 Q4	$39K	Hold	667	–	–	0.04%	53
2021 Q3	$55K	Hold	667	–	–	0.06%	50
2021 Q2	$63K	Hold	667	–	–	0.07%	50
2021 Q1	$43K	Hold	667	–	–	0.05%	50
2020 Q4	$39K	Hold	667	–	–	0.05%	54
2020 Q3	$14K	Hold	667	–	–	0.02%	54
2020 Q2	$11K	Hold	667	–	–	0.02%	53
2020 Q1	$9K	Hold	667	–	–	0.02%	52
2019 Q4	$14K	Hold	667	–	–	0.02%	56
2019 Q3	$21K	Hold	667	–	–	0.03%	53
2019 Q2	$15K	Hold	667	–	–	0.02%	57
2019 Q1	$26K	Hold	667	–	–	0.02%	81
2018 Q4	$30K	Hold	667	–	–	0.03%	76
2018 Q3	$29K	Hold	667	–	–	0.02%	79
2018 Q2	$27K	Buy	+667	New	+$23.2K	0.02%	84

Other funds holding VTGN

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NIP

Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Garrison Bradford & Associates's VTGN Position: Q2 2022 in Review

Garrison Bradford & Associates sold out of VistaGen Therapeutics (VTGN) in Q2 2022, closing a stake of 667 shares — an estimated $25K sold.

Garrison Bradford & Associates first reported a position in VTGN in Q2 2018 and held it in 16 quarters. The position peaked at $63K in Q2 2021. 112 funds tracked by Wall St. Rank hold VTGN as of Q2 2022.

Garrison Bradford & Associates reported no remaining VistaGen Therapeutics position as of Q2 2022 after selling out during the quarter.
Garrison Bradford & Associates sold 667 VistaGen Therapeutics shares in Q2 2022, an estimated $25K.
Garrison Bradford & Associates first reported a position in VistaGen Therapeutics in Q2 2018 and held it in 16 quarters.
Garrison Bradford & Associates's VistaGen Therapeutics position peaked at $63K in Q2 2021.
112 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2022.

Based on Garrison Bradford & Associates's 13F filing for Q2 2022, filed 23 Aug 2022.